CAR T-cell therapy for relapsed kappa myeloma
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a new treatment called CAR T-cells (your own immune cells engineered in the lab) designed to fight kappa-restricted multiple myeloma that has come back or stopped responding to standard drugs. The goal is to see if this treatment can help patients whose cancer has progressed despite previous therapies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have kappa-restricted multiple myeloma that has returned or stopped responding to treatment after at least 2 prior therapy lines
- You have received at least one proteasome inhibitor and one immunomodulatory drug as part of your previous treatments
- Your heart, lungs, kidneys, and liver function are adequate (will be checked with blood tests and heart imaging)
- You have adequate blood cell counts (hemoglobin, neutrophils, platelets, lymphocytes within safe ranges)
- You are at least 18 years old and in good enough overall health (ECOG score 0–2) with a life expectancy of at least 3 months
- You are willing to use effective contraception for at least 2 months after cell infusion if you can become pregnant or father children
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immunotherapy called CAR T-cell therapy for people with multiple myeloma that has returned or not responded to standard treatments. The therapy uses your own immune cells, modified to attack the cancer, which may help you achieve a remission.
This trial tests a new treatment using your own immune cells (called CAR-T cells) to fight multiple myeloma that has returned or not responded to earlier treatments. The treatment is designed to target and kill myeloma cells more effectively.
This study tests a new type of cell therapy called CAR-T, which uses your own immune cells to fight the cancer. It is for people with multiple myeloma that has come back or not responded to at least three previous treatments.
This trial tests a new type of cell therapy (CAR-T cells) that targets two proteins, BCMA and GPRC5D, on myeloma cells. It aims to see if it is safe and effective for people whose multiple myeloma has come back or stopped responding to at least three previous treatments.
This Phase 1 trial tests a CAR T-cell treatment made to target a protein called GPRC5D on myeloma cells. It may help patients whose multiple myeloma or plasma cell leukemia has come back or stopped responding to prior treatments.
This trial tests a new treatment where your own immune cells (T cells) are collected, modified to find and attack myeloma cells, and given back to you. It is for people with multiple myeloma that has come back or not responded to several standard treatments.
Hear when a new Relapsed/Refractory Multiple Myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.